Navigation Links
Angioplasty death risk reduced by doubling drug dose

A new study shows how the risk of death and heart attack can be reduced for heart patients undergoing an angioplasty. It was found that doubling the usual dose of an anti-clotting drug before the procedure is the answer.//

Angioplasty is a procedure in which a balloon-tipped catheter is threaded into an artery. The balloon is inflated to compress plaque in the artery and unblock the vessel. A small synthetic tube - stent is used to hold the vessel open, but arteries often re-close if blood clots form to protect the body against bleeding.

Patients commonly take the drug clopidogrel (Plavix) before angioplasty to prevent clotting. In this new study, patients received either the standard dose of 300 milligrams or received a dose of 600 milligrams before the procedure.

Following angioplasty it was found out that, 12 percent of patients who took the lower dose died, had a heart attack or needed another procedure. In contrast, only 4 percent of patients in the high-dose group had such an event. Doubling the dosage did not increase the risk of bleeding.

In conclusion, it was evident that the high-dose patients had a 48-percent reduction in heart attack risk compared to those given the standard dose. Additionally, a subgroup of patients taking the higher dose as well as the cholesterol-lowering drugs called statins had an 80-percent reduction.
'"/>




Page: 1

Related medicine news :

1. Cholesterol Drug Helps After Angioplasty
2. Angioplasty Should be the Standard
3. The Success Rate Of Angioplasty In Female Patients Low
4. Angioplasty The Much Preferred Treatment Of Choice For Heart Attacks
5. Angioplasty death risk reduced by doubling drug dose
6. A ray of hope in Angioplasty dilemma
7. Angioplasty plus stenting better than thrombolysis for elderly patients with AMI
8. Patients Fare Better With Doctors Who Do More Angioplasty Procedures
9. Researchers Begin Study To Find Out If Angioplasty Can Be Safely Done In Smaller Hospitals
10. Drug-Coated Stents Work Better In Diabetic Patients After Angioplasty
11. Togadiyas Condition Stable After Undergoing Angioplasty
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... , ... February 12, 2016 , ... Vail knee specialist ... Physician Leaders to Know in 2016 . The list consists of physicians establishing, leading ... to establish this list. , An Ambulatory Surgery Center, also known as an ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... of the Pittsburgh metro area, celebrates the beginning of the latest charity campaign ... develop social skills through art. Donations to this worthy cause are currently being ...
(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is ... to their Miami dental office. Beginning in January, Miami Dental Specialists will offer the ... Specialists are the first office to be chosen by the dental implant manufacturer, Straumann, ...
(Date:2/12/2016)... ... 12, 2016 , ... J Thomas & Associates Insurance Agency, ... to act as Agents of Change in the community, announces a new partnership ... to fulfill immediate needs and help them move into permanent housing. Donations to ...
(Date:2/12/2016)... OR (PRWEB) , ... February 12, 2016 , ... ... an article about foods choices that promote eye health. These articles generally list ... health. Water and health advocate Sharon Kleyne endorses every one of these lists ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Calif. , Feb. 12, 2016  SI-BONE, Inc., a medical ... ® ("iFuse"), a minimally invasive surgical (MIS) device indicated for ... National Government Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering ... , Maine , Massachusetts ... , New York , Rhode Island ...
(Date:2/12/2016)... Calif. , Feb. 12, 2016  Sequent Medical, ... in a study to evaluate the safety and effectiveness ... the treatment of ruptured intracranial aneurysms.  Prof Laurent ... Hospital, in Paris, France and ... patient. France and Germany.  ...
(Date:2/12/2016)... Lilly and Company (NYSE: LLY ) today announced that ... regimen patent would not presently be infringed by Actavis marketing ... Italy and Spain ... solution.  --> --> ... that Lilly,s patent would be indirectly infringed by Actavis marketing ...
Breaking Medicine Technology: